论文部分内容阅读
炭疽病是由炭疽杆菌引起的一种高传染性和致死率的疾病。炭疽毒素抗体治疗能有效降低炭疽病的发病率和死亡率,已成为炭疽病治疗的重要疗法之一。瑞西巴库是第一个获批的单克隆抗毒素抗体,对于疑似感染者,可同时注射瑞西巴库和炭疽疫苗以加强免疫。对于吸入性炭疽病,可与其他相关抗生素一起用于治疗炭疽病。瑞西巴库通过阻止炭疽毒素保护性抗原元件与宿主中相应受体结合的方式,防止毒素对宿主造成伤害。临床试验表明该药使用安全,动物实验证实该药在治疗与预防吸入性炭疽方面颇为有效。本文对炭疽病的病理生理特征和瑞西巴库的作用机制、疗效以及注意事项作简要概述。
Anthrax is a highly contagious and lethal disease caused by Bacillus anthracis. Anthrax toxin antibody treatment can effectively reduce the morbidity and mortality of anthrax and become one of the important treatments for anthrax. Ruixi Baku is the first monoclonal anti-toxin antibody that has been approved and may be used to boost the immune system by injecting both Ruixi Baku and anthrax vaccine simultaneously for suspected infections. For inhalation anthracnose, anthrax can be used in combination with other related antibiotics. Ruixi Baku prevents the toxins from damaging the host by preventing the anthrax toxin protective antigen components from binding to the corresponding receptors in the host. Clinical trials show that the drug is safe to use, animal experiments confirmed that the drug in the treatment and prevention of inhaled anthrax quite effective. In this paper, the pathophysiological characteristics of anthracnose and Ruixi Baku mechanism, efficacy and precautions for a brief overview.